EVALUATION OF CLINICAL EFFICIENCY OF CENTRALIZED MONITORING SYSTEM OF INTERNATIONAL NORMALIZED RATIO IN PATIENTS WITH ARTIFICIAL HEART VALVES
Abstract
The aim of the study is to evaluate the clinical efficacy of centralized blood monitoring of the internationally normalized ratio in patients with artificial heart valves.
Materials and methods. Comparison of different approaches to the organization of monitoring indicators of the international normalized ratio is made. The first group of 136 patients is observed in the system of centralized monitoring of the indicator, the second group of 62 people is observed by the doctors of medical institutions at the place of residence of patients. Thromboembolic
and hemorrhagic complications are evaluated.
Results. The average time for an international normalized ratio in the blood in the therapeutic range in patients of the first group is 73.2 %, in the second it is 40.1 % respectively. Significantly more thromboembolic and hemorrhagic complications in patients outside the centralized monitoring system are recorded
About the Authors
Yu. M. Stoiko
Extension Course Institute for Medical Practitioners, N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
M. N. Zamyatin
Extension Course Institute for Medical Practitioners, N. I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
M. V. Khruslov
Kursk Regional Clinical Hospital
Russian Federation
Russian Federation
I. V. Ponomareva
Kursk State Medical University
Russian Federation
Russian Federation
References
1. Дземешкевич С. Л., Панченко Е. П. Антикоагулянтная терапия у пациентов с клапанными пороками сердца // РМЖ. 2001. Т. 9. № 10. С. 427–430.
2. Задионченко В. С., Шехян Г. Г., Щикота А. М., Ялымов А. А. Место Варфарина в лечении и профилактике тромбоэмболий // РМЖ. Кардиология. 2011. № 26. С. 1648–1658.
3. Guyatt G. H., Akl E. A., Crowther M. et al. Antithrombotic Therapy and Prevention of Thrombosis. 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest. 2012. Vol. 141. № 2. P. 48–52.
4. Vongpatanasin W., Hillis L. D., Lange R. A. Prosthetic heart valves // N Engl J Med. 1996. Vol. 335. Iss. 6. P. 407–416.
5. Марцевич С. Ю., Лукина Ю. В. Варфарин и его значение в эру новых оральных антикоагулянтов. Вопросы контроля эффективности и безопасности лечения // Рацион. фармакотерапия в кардиологии. 2017. Т. 13. № 5. С. 699–705.
6. Рекомендации ESC по диагностике и ведению пациентов с острой эмболией системы легочной артерии. 2014 // Рос. кардиол. журн. 2015. Т. 20, № 8. С. 67–110.
7. Черняков А. В., Варданян Д. М. Использование препарата варфарин в хирургической практике // РМЖ. Хирургия. 2013. № 26. С. 1747–1750.
8. Напалкова О. С., Эмануэль В. Л., Карпенко М. А., Лапин С. В. Использование программного обеспечения «DAWN AC» для контроля назначения варфарина в условиях специализированной антикоагулянтной клиники // Учен. зап. СПбГМУ им. И. П. Павлова. 2015. № 2. С. 32–35.
9. Сычев Д. А., Кукес В. Г. Отечественный опыт применения фармакогенетического тестирования для персонализации дозирования варфарина: реальная возможность для российского врача // Consilium Medicum. 2013. Т. 15. № 10. С. 111–115.
10. Heu M. K., Welborn T., Nagykaldi Z. Clinical Question: In Adult Patients on Warfarin, does-Home-Self-Testing of Prothrombin Time and/or International Normalized Ratio Provide the Same Outcomes Compared to Testing by a Home Health Nurse or in a Clinical Setting? // J Okla State Med Assoc. 2016. № 109 (3). P. 99–100.
11. Poller L., Keown M., Ibrahim S., Lowe G. et al. A Multicentre Randomised Assessment of the DAWN AC Computer-Assisted Oral Anticoagulant Dosage Program // Thromb Haemost. 2009. Vol. 101. № 3. P. 487–494.
12. Connock M., Stevens C., Fry-Smith A. et al. Clinical Effectiveness and Cost-Effectiveness of Different Models of Managing Long-Term Oral Anticoagulation Therapy: A Systematic Review and Economic Modeling // Health Technol Assess. 2007. Vol. 11. № 38. P. iii-iv, ix-66.
13. Jowett S. et al.The Cost-Effectiveness of Computer-Assisted Anticoagulant Dosage: Results from the European Action on Anticoagulation (EAA) Multicentre Study // J Thromb Haemost. 2009. Vol. 7. № 9. P. 1482–1490.
14. Хруслов М. В., Лобачев В. И., Уханова И. Ю. Эффективность централизованного мониторинга международного нормализованного отношения прилечении варфарином // Тромбоз, гемостаз и реология. 2014. № 1 (57) . С.36–40.
15. Fihn S. D. et al. Risk Factors for Complications of Chronic Anticoagulation. A Multicenterstudy. Warfarin Optimized Outpatient Follow-up Study Group // Ann Intern Med. 1993. Vol. 118. № 7. P. 511–520.
16. Rosendaal F. R. et al. A method to Determine the Optimal Intensity of Oral Anticoagulant Therapy // Thromb Haemost. 1993. Vol. 69. № 3. P. 236–239.
17. Sjogren V. et al. Safety and Efficacy of well Managed Warfarin. A Report from the Swedish Quality Register Auricula // Thromb Haemost. 2015. Vol. 113. № 6. P. 1370–1377.
18. De Caterina R. et al. Vitamin K Antagonists in Heart Disease: Current Status and Perspectives (Section III). Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease // Thromb Haemost. 2013. Vol. 110. № 6. P. 1087–1107.
19. Новикова Н. А., Воловченко А. Н. Варфарин: место в современной антикоагулянтной терапии // Атеротромбоз. 2016. № 1. С. 50–58.
20. Lader E. et al. Warfarin Therapeutic Monitoring: is 70 % Time in the Therapeutic Range the Best we can do? // J Clin Pharm Ther. 2012. Vol. 37. № 4. P. 375–377.
Review
For citations:
Stoiko Yu.M., Zamyatin M.N., Khruslov M.V., Ponomareva I.V. EVALUATION OF CLINICAL EFFICIENCY OF CENTRALIZED MONITORING SYSTEM OF INTERNATIONAL NORMALIZED RATIO IN PATIENTS WITH ARTIFICIAL HEART VALVES. Vestnik SurGU. Meditsina. 2019;(1 (39)):21-25. (In Russ.)
Views:
162
Email this article 
